» Articles » PMID: 31330817

Platelets As Key Factors in Hepatocellular Carcinoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Jul 24
PMID 31330817
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a primary liver cancer that usually develops in the setting of chronic inflammation and liver damage. The hepatic microenvironment plays a crucial role in the disease development, as players such as hepatic stellate cells, resident liver macrophages (Kupffer cells), endothelial cells, extracellular matrix, and a variety of immune cells interact in highly complex and intertwined signaling pathways. A key factor in these cross-talks are platelets, whose role in cancer has gained growing evidence in recent years. Platelets have been reported to promote HCC cell proliferation and invasion, but their involvement goes beyond the direct effect on tumor cells, as they are known to play a role in pro-fibrinogenic signaling and the hepatic immune response, as well as in mediating interactions between these factors in the stroma. Anti-platelet therapy has been shown to ameliorate liver injury and improve the disease outcome. However, platelets have also been shown to play a crucial role in liver regeneration after organ damage. Therefore, the timing and microenvironmental setting need to be kept in mind when assessing the potential effect and therapeutic value of platelets in the disease progression, while further studies are needed for understanding the role of platelets in patients with HCC.

Citing Articles

Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response.

Baquero C, Iniesta-Gonzalez M, Palao N, Fernandez-Infante C, Cueto-Remacha M, Mancebo J J Pathol. 2025; 265(4):502-517.

PMID: 39989399 PMC: 11880977. DOI: 10.1002/path.6403.


Integration of single-cell and bulk analysis reveals TBXAS1 as a key platelet-related gene causing poor prognosis in osteosarcoma.

Liu H, Da W, Mu J, He X, Li Z, Gong T Front Genet. 2024; 15:1519529.

PMID: 39720182 PMC: 11667113. DOI: 10.3389/fgene.2024.1519529.


Predictive role of neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index for mortality in patients with MASLD.

Dong K, Zheng Y, Wang Y, Guo Q Sci Rep. 2024; 14(1):30403.

PMID: 39638820 PMC: 11621551. DOI: 10.1038/s41598-024-80801-8.


Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.

Yang F, Li O, Gao B, Chen Z, Li B, He J J Cancer Res Clin Oncol. 2024; 150(10):470.

PMID: 39436427 PMC: 11496351. DOI: 10.1007/s00432-024-05960-7.


Daily Antiplatelets Other Than Aspirin Reduce Liver Cancer Risk but Increase Intracranial Hemorrhage Risk in Cirrhotic Patients.

Lee C, Lin C, Yen T, Hsieh S Int J Gen Med. 2024; 17:4755-4767.

PMID: 39435412 PMC: 11492919. DOI: 10.2147/IJGM.S472260.


References
1.
Nieswandt B, Hafner M, Echtenacher B, Mannel D . Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999; 59(6):1295-300. View

2.
Semenov A, Romanov Y, Loktionova S, Tikhomirov O, Khachikian M, Vasilev S . Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc). 1999; 64(11):1326-35. View

3.
Poon R, Ng I, Lau C, Yu W, Fan S, Wong J . Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg. 2001; 182(3):298-304. DOI: 10.1016/s0002-9610(01)00708-5. View

4.
Pinzani M . PDGF and signal transduction in hepatic stellate cells. Front Biosci. 2002; 7:d1720-6. DOI: 10.2741/A875. View

5.
Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View